|
Indications and Dosage
Parenteral
Severe invasive amoebiasis Adult: Dose may be given via IM or SC inj. For full dosing guidelines, refer to product information.
|
|
Contraindications
Cardiac, renal or neuromuscular disease. Avoid use in pregnancy.
|
|
Special Precautions
Avoid contact with mucous membranes as it is an irritant. Close supervision and ECG monitoring is recommended during treatment. Children, elderly and debilitated patients. Avoid chronic use as drug accumulation may lead to potentially fatal toxicity.
|
|
Adverse Reactions
Muscle ache, tenderness, stiffness and weakness at the Inj site; necrosis and abscess formation. Diarrhoea, nausea and vomiting; dizziness and headache. Rarely, mild sensory disturbances; eczematous, urticarial and purpuric skin lesions. CV effects, changes in the ECG particularly flattening or invasion of the T-wave and prolongation of the QT interval. Lesions of the heart, GIT, kidneys, liver and skeletal muscle with large doses or prolonged administration.
Potentially Fatal: Severe acute degenerative myocarditis which may give rise to sudden cardiac failure and death. |
|
Action
Description:
Mechanism of Action: Emetine, an alkaloid of ipecac and a tissue amoebicide acts principally in the bowel wall and in the liver. It is used in the treatment of severe invasive amoebiasis. Pharmacokinetics: Distribution: After inj, emetine is concentrated mainly in the liver and to a certain degree, it is also found in the kidneys, lungs and spleen. Excretion: Slow excretion and amounts may still be detected in the urine 40-60 days after treatment has stopped. |
|
MIMS Class
|
Sign Out
